Jan 30, 2023
We are delighted to announce that Oximio Israel has been successfully awarded yet another import license for Compassionate use program in January 2023. “Compassionate use” allows for a patient outside of clinical trials with a serious or life-threatening disease to...
Jan 20, 2023
We are delighted to share that expansion of our global bonded depot network continues. We have successfully received the bonded depot license this week for our Serbia facility. This opens a route for imports of bulk shipments and distribution from our depot in...
Jan 16, 2023
As Oximio patient centricity services continue to expand, we are delighted to announce that the first home healthcare visit in Israel took place week commencing 9th of January 2023. The services allow for the nurses to collect the bio-samples from the patients’...
Dec 12, 2022
Following the announcement of 8th December 2022, the Board of Oximio confirms the appointment of Mykola Nikolaiev as the new Chief Executive Officer (CEO). Accordingly, Krisztina Varga has resigned from the Board as CEO and Mykola Nikolaiev takes over the...
Apr 1, 2022
Following the crisis in Ukraine, Oximio has resumed some operations, knowing that previously established supply chains and logistics models are no longer feasible. This is given to the destruction of infrastructure, stock limitations, and most importantly, as we...
